RYZ801
Hepatocellular Carcinoma
PreclinicalActive
Key Facts
About RayzeBio
RayzeBio is a San Diego-based radiopharmaceutical company founded in 2020, specializing in targeted alpha therapies using actinium-225. The company has built a pipeline of drug candidates aimed at various solid tumors and was acquired by Bristol Myers Squibb, indicating strong validation of its platform and pipeline. RayzeBio's approach combines a proprietary targeting moiety with a potent radioactive payload to deliver precise, tumor-killing radiation while aiming to minimize damage to healthy tissues.
View full company profileTherapeutic Areas
Other Hepatocellular Carcinoma Drugs
| Drug | Company | Phase |
|---|---|---|
| Namodenoson (CF102) | Can Fite Biopharma | Phase IIb/III |
| GC-101 | Genocury Biotech | Preclinical |
| DCR-MYC | Dicerna Pharmaceuticals | Preclinical |
| CT011 | CARsgen Therapeutics | Phase II |
| BRVT101 | Biorevert | Preclinical |
| BRVT121 | Biorevert | Phase I |
| BRVT151 | Biorevert | Phase I |
| HCC Diagnostic Test | Senseera | Clinical POC |
| RG6139 (RO7247669) | Chugai Pharmaceutical | Phase III |
| ALN-BCAT | Alnylam Pharmaceuticals | Phase 1 |
| HCC Program | Arcellx | Discovery |
| TTFields | Novocure | Pilot |